COVID-19: challenges of viral variants

JL Jacobs, G Haidar, JW Mellors - Annual Review of Medicine, 2023 - annualreviews.org
The COVID-19 pandemic has been accompanied by SARS-CoV-2 evolution and
emergence of viral variants that have far exceeded initial expectations. Five major variants of …

Severity of the Omicron SARS‐CoV‐2 variant compared with the previous lineages: A systematic review

M Arabi, Y Al‐Najjar, N Mhaimeed… - Journal of Cellular …, 2023 - Wiley Online Library
The Omicron variant was first detected in October 2021, which evolved from the original
SARS‐CoV‐2 strain and was found to possess many mutations. Immune evasion was one of …

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …

AS Lauring, MW Tenforde, JD Chappell, M Gaglani… - bmj, 2022 - bmj.com
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …

[HTML][HTML] Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods …

AD Iuliano - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period
Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December …

Public health impact of covid-19 vaccines in the US: observational study

AB Suthar, J Wang, V Seffren, RE Wiegand, S Griffing… - Bmj, 2022 - bmj.com
Objective To evaluate the impact of vaccine scale-up on population level covid-19 mortality
and incidence in the United States. Design Observational study. Setting US county level …

Protection against Omicron from vaccination and previous infection in a prison system

ET Chin, D Leidner, L Lamson, K Lucas… - … England Journal of …, 2022 - Mass Medical Soc
Background Information regarding the protection conferred by vaccination and previous
infection against infection with the B. 1.1. 529 (omicron) variant of severe acute respiratory …

Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study

H Mukae, H Yotsuyanagi, N Ohmagari… - Clinical Infectious …, 2023 - academic.oup.com
Background This phase 2b part of a randomized phase 2/3 study assessed the efficacy and
safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the …

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

L Chu, K Vrbicky, D Montefiori, W Huang… - Nature medicine, 2022 - nature.com
Rising breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in previously immunized individuals have raised concerns for the need for a booster …

[HTML][HTML] COVID-19 incidence and mortality among unvaccinated and vaccinated persons aged≥ 12 years by receipt of bivalent booster doses and time since …

AG Johnson - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
COVID-19 vaccine effectiveness decreased with waning of vaccine-derived immunity and
emerging Omicron sublineages. An updated (bivalent) booster dose enhances protection …

The epidemiology of long coronavirus disease in US adults

MKM Robertson, SA Qasmieh… - Clinical Infectious …, 2023 - academic.oup.com
Background We estimated the prevalence of long COVID and impact on daily living among a
representative sample of adults in the United States. Methods We conducted a population …